Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was not the case as the company failed to prepare clinicians and payors adequately, leading to delays in adoption [6][7]. - The launch of Inspire V faced significant challenges, including weak demand due to customers having excess inventory of older devices and delays in training and software updates necessary for billing [8][9]. Stock Performance - Following the announcement of an "elongated timeframe" for the Inspire V launch and a reduction in 2025 earnings per share guidance by over 80%, Inspire's stock price dropped by $42.04, or more than 32%, from $129.95 to $87.91 per share between August 4 and August 5, 2025 [8][9].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the poor launch of its new product, Inspire V, which was marked by significant operational failures and misrepresentations to investors [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between August 6, 2024, and August 4, 2025 [1]. - Defendants are accused of making false statements regarding the successful launch of Inspire V, while in reality, demand was low and providers had excess inventory [2]. - Key operational failures included inadequate training for treatment center customers, unestablished IT systems, and lack of Medicare reimbursement at launch [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand [5][6]. - The company faced challenges such as implanting centers not completing required training and software updates for claims processing not being effective until July 1, 2025, which hindered billing for procedures [7]. Stock Performance - Following the announcement of an "elongated timeframe" for the Inspire V launch and a reduction in 2025 earnings per share guidance by over 80%, Inspire's stock price plummeted by $42.04, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Points - The Gross Law Firm has issued a notice to shareholders of Inspire Medical Systems, Inc. regarding a class action lawsuit related to the company's product launch failures [1][3] - The class period for the lawsuit is from August 6, 2024, to August 4, 2025, during which shareholders are encouraged to register for potential recovery [3][4] - Allegations include that the launch of Inspire V was poorly executed, with significant inventory issues and inadequate preparations, contrary to the company's assurances [3] Company Overview - Inspire Medical Systems, Inc. is facing allegations of making false statements regarding the successful launch of its new product, Inspire V [3] - The company reportedly failed to complete essential tasks for the product launch, including training for treatment centers and updating necessary IT systems [3] Legal Proceedings - Shareholders have until January 5, 2026, to register for the class action and potentially be appointed as lead plaintiffs [4] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements by the company [5]

Core Insights - Inspire Medical Systems, Inc. specializes in innovative medical solutions for sleep apnea treatments, particularly through its Inspire therapy device, which serves as an alternative to CPAP machines [1] - Piper Sandler has set a price target of $165 for INSP, indicating a potential upside of 20.61% from the current trading price of $136.81 [1][6] Legal Issues - Inspire Medical is currently facing a class action lawsuit led by the Schall Law Firm, alleging violations of the Securities Exchange Act of 1934 related to securities fraud [2][5] - The lawsuit targets investors who purchased INSP securities between August 6, 2024, and August 4, 2025, with affected shareholders encouraged to contact the law firm by January 5, 2026 [3] Stock Performance - As of the latest update, INSP's stock price is $136.81, reflecting a decrease of 2.30% or $3.22, with trading fluctuations between $136.61 and $142.26 [4] - Over the past year, INSP has experienced significant volatility, with a high of $216.01 and a low of $70.77, and currently holds a market capitalization of approximately $4.05 billion [4][6]

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the launch and performance of its Inspire V Device, which has resulted in significant financial losses for investors [1][3][5]. Company Overview - Inspire Medical Systems, Inc. is a medical technology company that develops and manufactures an implantable device for treating obstructive sleep apnea, known as the Inspire V Device [1][3]. Allegations and Issues - The lawsuit claims that the company misled investors about the Inspire V Device's launch, which was described as groundbreaking but ultimately faced poor demand and significant operational failures [3][4]. - Key failures included inadequate training for treatment centers, lack of essential IT systems, and unpreparedness for insurance claims processing, which were critical for a successful product launch [4]. Financial Impact - On August 4, 2025, the company announced a drastic reduction in its 2025 earnings guidance by over 80%, leading to a stock price drop of $42.04 per share (over 32%) in one day, erasing $1.2 billion in market capitalization [5]. - From a high of $216.71 per share on September 23, 2024, the stock price plummeted by $127.00 per share (nearly 60%), resulting in billions of dollars lost in market capitalization [5].

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. SOURCE The Gross Law Firm The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: [email protected] Phone: (646) ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption [6][7]. - The launch faced weak demand as many customers had excess inventory of older devices, which contributed to the poor market reception of Inspire V [7]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [8]. - Following this announcement, Inspire's stock price fell by $42.04 per share, a decline of more than 32%, dropping from $129.95 to $87.91 between August 4 and August 5, 2025 [9].

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the lawsuit is from August 6, 2024, to August 4, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A class action lawsuit has already been filed, and investors wishing to serve as lead plaintiffs must act by January 5, 2026 [4][6]. Group 2: Allegations Against Inspire Medical - The lawsuit alleges that Inspire Medical misrepresented and failed to disclose critical information regarding the Inspire V sleep apnea device, including its actual market demand and the necessary steps for its launch [6]. - Defendants are accused of issuing materially false and misleading statements that led investors to believe in strong demand for the Inspire V device, resulting in investor damages when the true situation was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions of dollars for investors [5]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at that time and ranking highly in the number of settlements since 2013 [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand [5][6]. - Specific issues cited include incomplete training and onboarding at implanting centers, delayed software updates for claims processing, and existing excess inventory of older devices among customers [7]. Stock Performance - Following the announcement of an "elongated timeframe" for the Inspire V launch and a reduction in 2025 earnings per share guidance by over 80%, Inspire's stock price plummeted by $42.04, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].